At least 68 vaccine candidates under development
The development of vaccines against SARS-CoV-2 is progressing at an unparalleled speed. As of the 29th of March, there were at least 68 vaccine candidates comprising several different vaccine designs, including whole killed virus, subunit, attenuated, viral vector, DNA and mRNA vaccines. Whilst it usually takes 10-15 years to develop a vaccine, it has only taken just over 9 weeks from the publication of the viral genetic sequence for the first vaccine candidate to reach clinical testing. Development has been expediated by using existing technological platforms and by performing preclinical and clinical testing simultaneously.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:117 |
|---|---|
| Enthalten in: |
Lakartidningen - 117(2020) vom: 06. Apr. |
| Sprache: |
Schwedisch |
|---|
| Weiterer Titel: |
Minst ett 70-tal möjliga vacciner mot sars-cov-2 är nu på gång |
|---|
| Beteiligte Personen: |
Leach, Susannah [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 17.04.2020 Date Revised 18.12.2020 published: Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM308779681 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308779681 | ||
| 003 | DE-627 | ||
| 005 | 20231225132456.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||swe c | ||
| 028 | 5 | 2 | |a pubmed24n1029.xml |
| 035 | |a (DE-627)NLM308779681 | ||
| 035 | |a (NLM)32293018 | ||
| 035 | |a (PII)F3MZ | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a swe | ||
| 100 | 1 | |a Leach, Susannah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a At least 68 vaccine candidates under development |
| 246 | 3 | 3 | |a Minst ett 70-tal möjliga vacciner mot sars-cov-2 är nu på gång |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.04.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The development of vaccines against SARS-CoV-2 is progressing at an unparalleled speed. As of the 29th of March, there were at least 68 vaccine candidates comprising several different vaccine designs, including whole killed virus, subunit, attenuated, viral vector, DNA and mRNA vaccines. Whilst it usually takes 10-15 years to develop a vaccine, it has only taken just over 9 weeks from the publication of the viral genetic sequence for the first vaccine candidate to reach clinical testing. Development has been expediated by using existing technological platforms and by performing preclinical and clinical testing simultaneously | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, DNA |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Lakartidningen |d 1965 |g 117(2020) vom: 06. Apr. |w (DE-627)NLM000007544 |x 1652-7518 |7 nnns |
| 773 | 1 | 8 | |g volume:117 |g year:2020 |g day:06 |g month:04 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 117 |j 2020 |b 06 |c 04 | ||